Is Semaglutide the Same as Ozempic?
Wondering if semaglutide and Ozempic® are the same? Learn the difference between the ingredient and brand name, and what it means for your care.
Discover potential semaglutide side effects, how they may impact you, and what to ask a licensed provider before starting.
Semaglutide, a GLP-1 receptor agonist, is FDA-approved for managing type 2 diabetes and, under specific brand names, chronic weight management. As public awareness grows, so does curiosity about potential side effects.
This article addresses the most frequently asked questions about semaglutide side effects, drawing on current clinical evidence. Whether you're considering a conversation with a licensed healthcare provider or simply want to be better informed, this resource will help you navigate your options with clarity and confidence.
Semaglutide is part of a class of medications known as GLP-1 receptor agonists. These drugs mimic the action of the body’s natural GLP-1 hormone, which plays a role in insulin secretion and appetite regulation.
The medication is available under brand names such as Ozempic® and Wegovy®, both of which are FDA-approved for different indications. Ozempic® is approved for managing type 2 diabetes, while Wegovy® is approved for chronic weight management in specific populations.
Eden does not dispense semaglutide or any medication. Instead, Eden connects individuals with independent, licensed healthcare providers who can evaluate eligibility and, if appropriate, prescribe treatment through a state-licensed pharmacy.
{{primary-cta}}
Clinical trials suggest that semaglutide may cause mild to moderate side effects, especially when beginning treatment or adjusting the dosage. The most commonly reported side effects include:
These effects may occur during the initial dosage escalation period and may lessen over time as the body adjusts. According to data from the STEP 1 trial, gastrointestinal issues were the most frequently reported side effects, particularly during the first 8 to 12 weeks.
The GLP-1 formulation used in this trial is the same as what was later approved and marketed under the brand name Wegovy®, specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.
Though less common, semaglutide may be associated with more serious adverse events. These include:
In the STEP-1 trial, the incidence of serious side effects was low, but providers were advised to monitor for signs of these risks.
If any of these symptoms develop, it’s important to consult a licensed healthcare provider immediately or seek emergency care.
{{primary-cta}}
Some individuals report changes in mood or energy while taking GLP-1 medications, though this has not been established in large-scale clinical trials. In the STEP clinical program, which assessed the use of semaglutide in weight management, there was no statistically significant increase in adverse psychiatric effects compared to placebo. However, individual responses may vary, and the FDA recommends monitoring for new or worsening mood symptoms.
If you notice new or worsening mental health symptoms, speak with a licensed healthcare provider as soon as possible.
Although not listed as a side effect in clinical trials, some users have reported hair shedding during treatment. This may be tied to rapid body changes, nutritional shifts, or stress rather than semaglutide itself.
It’s essential to discuss any hair loss concerns with a licensed healthcare provider, who may recommend lab tests or dietary adjustments.
In a 2025 study published in Diabetes, Obesity, and Metabolism, researchers examined body composition changes in individuals taking semaglutide. They found that while most of the weight lost was fat, a portion of lean mass was also reduced.
To help preserve muscle, healthcare providers may recommend strategies like strength training and ensuring adequate protein intake.
Seek immediate medical attention if you experience:
These symptoms may indicate a serious reaction that needs urgent care. Always discuss concerns with a licensed healthcare provider who can assess your unique medical history.
{{primary-cta}}
Before beginning any GLP-1 treatment, a conversation with a licensed provider can help set expectations and ensure safety. Consider asking:
Eden helps you start that conversation by connecting you with independent, licensed healthcare providers who specialize in metabolic care.
Semaglutide may offer an effective approach for managing metabolic conditions under the guidance of a licensed provider. However, it’s essential to be informed about potential side effects, both common and rare, so you can make decisions that support your overall well-being.
With Eden, you can easily connect with trusted providers, get answers to your questions, and access treatment options that align with your goals.
Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.
Eden is not a medical provider or a pharmacy. Eden connects individuals with independent licensed healthcare providers who independently evaluate each patient to determine whether a prescription treatment program is appropriate. All prescriptions are written at the sole discretion of the licensed provider. Medications are filled by independent, state-licensed pharmacies. Eden does not manufacture, own, or dispense any medications. Please consult a licensed healthcare provider before making any medical decisions.
Chun, E., Siojo, N. A., Rivera, D., Reyna, K., Legere, H., Joseph, R., & Pojednic, R. (2025). Weight loss and body composition after compounded semaglutide treatment in a real world setting. Diabetes Obesity and Metabolism. https://doi.org/10.1111/dom.16162
Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183